行情

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

实时行情|Nasdaq Last Sale

0.3294
+0.0094
+2.94%
已收盘, 16:00 09/20 EDT
开盘
0.3112
昨收
0.3200
最高
0.3384
最低
0.3000
成交量
5.27万
成交额
--
52周最高
2.190
52周最低
0.2700
市值
842.97万
市盈率(TTM)
-0.5230
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PHIO 新闻

  • 沙特复产速度遭质疑 美油重上60美元仍可期
  • 汇通网.2小时前
  • 比亚迪:在德国斩获22台12米纯电动大巴订单
  • 新浪财经综合.2小时前
  • 欧元区经济增长接近停滞 制造业重挫的影响开始蔓延
  • 新浪财经综合.2小时前
  • 欧央行实现通胀目标之路 或事与愿违制造"减码恐慌"
  • 新浪财经综合.2小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

PHIO 简况

Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.
展开

Webull提供Phio Pharmaceuticals Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。